S
0.950
0.00 (0.00%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (GB) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | SYNAIRGEN PLC ORD 1P | - | - |
AIStockmoo Score
0.8
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.75 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| SYNAIRGEN PLC ORD 1P | 12 M | - | - | 1.21 |
| ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
| BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
|
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.57% |
| % Held by Institutions | 87.22% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |